The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2021 | ANCHOR: melflufen plus dexamethasone with bortezomib or daratumumab in myeloma
Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, shares an update on the Phase I/IIa ANCHOR trial (NCT03481556) investigating melflufen plus dexamethasone with bortezomib or daratumumab in patients with relapsed/refractory multiple myeloma. The overall response rate was 73% in combination with daratumumab, and 62% in bortezomib. Both arms exhibited a similar safety profile to melflufen plus dexamethasone therapy alone. The median progression-free survival (PFS) for combination with daratumumab was 12.9 months at a follow-up of 18.9 months. PFS data is not yet available for the bortezomib arm. This interview took place during the 2021 European Myeloma Network (EMN) congress.
